An irreversible inhibitor of Btk for use in the treatment of chronic lymphocytic leukemia having the formula D: ** Formula ** in which: La is CH2, O, NH or S； Ar is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl； Y is an optionally substituted group selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl； Z is C (>； = O), OC (>； = O), NHC (>； = O), C (>； = S), S (>； = O) x, OS (>； = O) x or NHS (>； = O ) x, where x is 1 or 2； R7 and R8 are independently selected from H, unsubstituted C1-C4 alkyl, substituted C1-C4 alkyl, unsubstituted C1-C4 heteroalkyl, substituted C1-C4 heteroalkyl, unsubstituted C3-C6 cycloalkyl, substituted C3-C6 cycloalkyl, C2 heterocycloalkyl -C6 unsubstituted and substituted C2-C6 heterocycloalkyl； or R7 and R8 together form a bond； R6 is H, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 heteroalkyl, C1-C6 alkoxyalkyl, C1-C8 alkylaminoalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted aryl, C2- heterocycloalkyl C8 substituted or unsubstituted, substituted or unsubstituted heteroaryl, (C1-C4) alkyl aryl, (C1-C4) alkyl heteroaryl, (C1-C4) alkyl cycloalkyl (C3-C8) or (C1-C4) alkyl heterocycloalkyl (C2 -C8) or a pharmaceutically acceptable salt thereof.Un inhibidor irreversible de Btk para usar en el tratamiento de la leucemia linfocítica crónica que tiene la fórmula D:**Fórmula** en la que: La es CH2, O, NH o S； Ar es un arilo sustituido o no sustituido o un heteroarilo sustituido o no sustituido； Y es un grupo opcionalmente sustituido seleccionado entre alquilo, heteroalquilo, cicloalquilo, heterocicloalquilo, arilo y heteroarilo； Z es C(>；=O), OC(>；=O), NHC(>；=O), C(>；=S), S(>；=O)x, OS(>；=O)x o NHS(>；=O)x, donde x es 1 ó 2； R7 y R8 se seleccionan independientemente entre H, alquilo C1-C4 no sustituido, alquilo C1-C4 sustituido, heteroalquilo C1-C4 no sustituido, heteroalquilo C1-C4 sustituido, c
